Back to Agenda
Electronic Submissions Demystified
Session Chair(s)
Tessa Brown, BSN, DRSC, MPH, RN
Super Office Deputy Director for Operations, DHHS/FDA/CDER/Office of Strategic Programs, United States
During this session, FDA and industry will provide a summary on electronic submissions. As of May 5, 2017 and May 5, 2018, eCTD is required for NDA, BLA, and ANDA and Commercial IND and DMF submissions, respectively. FDA will provide an update on submission metrics and industry will provide an overview of best practices for successful submission. Additionally, FDA will provide an update on requirements for drug registration and listing, which are intended to improve FDA and industry processes.
Learning Objective : Discuss the status of electronic submissions and validation at the FDA; Identify key components of lifecycle management for electronic submissions; Apply proposed best practices for handling daily submissions and ensuring validation standards are followed; Describe changes to the drug registration and listing regulation; Describe how to reserve a National Drug Code and certify a drug listing file.
Speaker(s)
Jonathan Resnick, PMP
Project Management Officer, OBI, OSP, CDER, FDA, United States
Sandra Krogulski, MA
Director, GRSO Innovation and Business Operations Lead, Bristol Myers Squibb, United States
Julian Chun, PHARMD, MBA
Pharmacist, DRLB, OUDLC, OC, CDER, FDA, United States
Have an account?